Abstract Number: 0509 • ACR Convergence 2021
Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Background/Purpose: Deucravacitinib is a novel, oral, allosteric agent that selectively inhibits intracellular signaling by binding to the tyrosine kinase 2 (TYK2) pseudokinase domain rather than…Abstract Number: 1820 • ACR Convergence 2021
Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease1, Atul Deodhar2, Désirée van der Heijde3, Frank Behrens4, Alan Kivitz5, Tom Lehman6, Lan Wei6, Marleen Nys7, Subhashis Banerjee6 and Miroslawa Nowak6, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 4CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, 5Altoona Center for Clinical Research, Duncansville, PA, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Braine-l'Alleud, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates IL-23, IL-12, and IFNα/β signaling. Deucravacitinib is a novel, oral selective inhibitor of TYK2…
ACR Meeting Abstracts